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treatment of systemic lupus erythematosus: 
evidence to date
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Abstract: B cells in general and BAFF (B cell activating factor of the tumor necrosis factor 
[TNF] family) in particular have been primary targets of recent clinical trials in systemic lupus 
erythematosus (SLE). In 2011, belimumab, a monoclonal antibody against BAFF, became the 
first biologic agent approved for the treatment of SLE. Follow-up studies have shown excellent 
long-term safety and tolerability of belimumab. In this review, we critically analyze blisibimod, 
a novel BAFF-neutralizing agent. In contrast to belimumab that only blocks soluble BAFF 
trimer but not soluble 60-mer or membrane BAFF, blisibimod blocks with high affinity all 
three forms of BAFF. Furthermore, blisibimod has a unique structure built on four high-affinity 
BAFF-binding peptides fused to the IgG1-Fc carrier. It was tested in phase I and II trials in SLE 
where it showed safety and tolerability. While it failed to reach the primary endpoint in a recent 
phase II trial, post hoc analysis demonstrated its efficacy in SLE patients with higher disease 
activity. Based on these results, blisibimod is currently undergoing phase III trials targeting 
this responder subpopulation of SLE patients. The advantage of blisibimod, compared to its 
competitors, lies in its higher avidity for BAFF, but a possible drawback may come from its 
immunogenic potential and the anticipated loss of efficacy over time.
Keywords: BAFF, APRIL, lupus, B cells, blisibimod
Introduction
The primary role of B cells in initiating systemic autoimmune diseases has long been 
suspected. Production of autoantibodies, formation of circulating immune complexes 
with subsequent Fc-receptor engagement, and activation of the complement system 
have been considered to play a primary role in tissue inflammation in systemic lupus 
erythematosus (SLE).
It has been well established that B cells are excellent antigen-presenting cells for 
antigens that can bind to their surface Ig receptors.1 Direct evidence for the role of 
B cells apart from autoantibody production was first demonstrated in mice carrying the 
lpr/lpr mutation which develop a lupus-like disease.2 When MRL-lpr/lpr mice were 
crossed to J
H
 knockouts, mice lacking B cells were generated. While their littermates 
with B cells developed nephritis and vasculitis and made autoantibodies, mice lacking 
B cells showed no evidence of renal disease or vasculitis. A similar effect was also 
observed in another lupus strain, NZM 2328, where absence of B cells completely 
protected mice from development of lupus.3 Subsequently, elegant experiments have 
shown that the requirement for B cells goes beyond their role as precursors of antibody-
secreting cells and likely reflects their ability to serve as (auto)antigen-presenting cells.4 
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This autoantibody-independent role of B cells has been 
demonstrated in experiments where a mutant transgene 
encoding surface Ig was introduced into MRL-lpr/lpr mice. 
While these mice failed to secrete serum antibodies, they 
still had functional B cells expressing surface Ig receptors. In 
contrast to mice that completely lack B cells, mice carrying 
a mutant gene for surface Ig developed mononuclear cellular 
infiltrates in their kidneys, the characteristic of lupus nephritis 
in this strain, and had increased mortality compared to con-
trols. These mice exhibited increased number of activated and 
memory CD4+ splenic T cells. Thus, this study showed that 
B cells themselves, independent of autoantibody secretion, 
likely play a primary pathogenic role in lupus.4–6
B cell processing of autoantigen can contribute to epitope 
spreading, a phenomenon in which initial reactivity to one 
epitope is followed by subsequent reactivity to additional 
epitopes expressed on the same or related autoantigens, a 
phenomenon commonly observed in lupus.7 B cells may 
additionally be a source of proinflammatory (ie, interleu-
kin-6 [IL-6], tumor necrosis factor alpha [TNF-α]) and/or 
regulatory cytokines (ie, IL-10),8 and abnormalities in this 
cytokine-producing function have been observed in lupus 
mice.9 Remarkably, B cells that lack one of the innate Toll-
like receptors, TLR9, may lose this regulatory function.10 
Based on these observations, the Shlomchik lab was the first 
to suggest that B cell depletion, instead of bare mechanical 
removal of autoantibodies by plasma exchange, should be 
considered as a primary target for treating lupus.
However, the essential requirement for B cells early in the 
course of the disease does not rule out an important contri-
bution from T cells, which serve downstream in the disease 
process as primary effector cells. For example, in autoimmune 
MRL-lpr/lpr mice, thymectomy or treatment with monoclonal 
T-cell-specific antibody could ameliorate lymphadenopathy 
and delay autoimmune-mediated inflammation.11,12
B cell hyperactivity has been recognized as an important 
characteristic of human SLE and animal models of lupus.13,14 
It is associated with polyclonal hypergammaglobulinemia 
and production of numerous autoantibodies, particularly 
those recognizing components of the nuclear chromatin 
(ie, histones and dsDNA) and certain extractable nuclear 
antigens (ie, Smith antigen and U1-RNP). These antibodies 
(against Smith and dsDNA) are highly specific for lupus.15,16 
Circulating levels of BAFF (B cell activating factor of the 
TNF family), a key B cell survival and activation factor, are 
elevated in SLE patients and in animal models of lupus.17–21 
It is hypothesized that BAFF can be at least partially respon-
sible for this activated B cell phenotype in lupus.
In this review, we discuss new discoveries relevant to 
BAFF’s role in the pathogenesis of SLE. We also discuss 
available therapeutics that specifically target human BAFF 
focusing on blisibimod, a novel high-potency tetravalent 
BAFF inhibitor. While other B cell-targeted approaches in 
SLE, such as B cell depletion with the anti-CD20 antibody 
rituximab, were largely unsuccessful,22–24 BAFF neutraliza-
tion with a monoclonal anti-BAFF antibody belimumab25 
met primary endpoints in two large phase III clinical trials 
leading to its approval in 2011 by the US Food and Drug 
Administration (FDA) for the treatment of adult patients 
with SLE.26,27
BAFF and its receptors
BAFF also known as Blys (B lymphocyte stimulator), 
TALL-1,28 and THANK,29 were discovered in 1999.30,31 
BAFF plays an essential role in B cell biology. Initial 
experiments suggested that BAFF may act as an important 
B cell growth factor by costimulating B cell proliferation 
induced by cross-linking of the B cell receptor for antigen. 
However, BAFF by itself fails to stimulate proliferation of 
resting B cells.30 It soon became clear that BAFF works 
by providing a critical B cell survival signal (rather than a 
proliferation signal). Consequently, mice deficient in BAFF 
have a marked reduction in B cell numbers, along with low 
serum Ig concentration.32 In contrast, excess production of 
BAFF causes an SLE-like disease in transgenic mice33,34 and 
likely plays a role in human SLE and other systemic autoim-
mune diseases.19–21,35
BAFF is produced by a variety of cell types including 
macrophages/monocytes, dendritic cells, and neutrophils.36 
While initial reports failed to detect BAFF expression in 
freshly isolated or activated T- and B cells,31 these cells can 
also make BAFF upon certain conditions.37
Similar to other members of the TNF family, BAFF can 
exist as a type II cell membrane-bound protein (285 amino 
acids) and as a soluble form. The furin protease cleaves 
the surface BAFF and releases the soluble form of this 
cytokine.30,38 Soluble BAFF can adopt at least two different 
configurations: a typical homotrimer (3-mer) or a capsid-
like structure that has 20 repeats of the 3-mer (60-mer).39 
All three forms of BAFF are biologically active and can 
contribute to cell signaling39 (Figure 1). BAFF can also 
form heterotrimers with another B cell survival molecule 
APRIL (a proliferation-inducing ligand, CD256). However, 
it is not well understood under which conditions these het-
erotrimers are formed. Interestingly, the phenotype of mice 
that only express the membrane form of BAFF but lack the 
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ability to make soluble BAFF is very similar to BAFF-de-
ficient mice suggesting that membrane BAFF under normal 
conditions exerts a very limited role in B cell biology.40
BAFF binds to three receptors: transmembrane activator 
and calcium modulator and cyclophilin ligand interactor 
(TACI, CD267), B-cell maturation antigen (BCMA, 
CD269), and BAFF receptor (BAFF-R, also known as BR3, 
CD268).38,41 BAFF-R solely interacts with BAFF, whereas 
another TNF-family member, APRIL, can bind and signal 
through the other two BAFF receptors, TACI and BCMA, but 
not through BAFF-R.38 APRIL also binds to heparin-sulfate 
proteoglycans (HSPGs), with 3 mers and multimers bound 
to HSPGs, also contributing to signaling. BAFF-R-deficient 
mice have a phenotype similar to BAFF-deficient mice,42,43 
while this is not the case with mice lacking either BCMA or 
TACI receptors.32,44
A very nice review by Mackay and Browning45 describes 
in much more detail the structure–function relationship 
between the existing ligands (BAFF and APRIL) and their 
respective receptors on B cells. Interestingly, the crystal 
structure of BAFF has revealed important differences 
between the BAFF and other members of the TNF family 
by revealing the existence of an extended loop in the BAFF, 
nonexistent in other TNF members, that may be involved in 
both receptor binding and viral-like assembly.
BAFF-R expression in B cells
Biotinylated and FLAG-tagged Blys/BAFF were initially 
used to search for BAFF-R receptor expression in different 
cell types. B cell tropism for BAFF was shown in peripheral 
CD20+ B cells, and in a variety of B cell tumor lines (ie, 
Raji, Namalwa, RPMI-8226), but not in bone marrow plasma 
cells, nor in T cells (resting or activated), monocytes, natural 
killer cells, granulocytes, or myeloid-derived cell lines.31 
Furthermore, human BAFF/Blys acted across the species 
as it could bind and induce proliferation of murine B cells. 
BAFF-R recruits TNF receptor-associated factor 3 (TRAF3), 
which then leads to downstream signaling cascade resulting 
in activation of c-jun terminal kinase and nuclear factor 
kappaB (NF-κB) pathways.46
Rationale for targeting BAFF in SLE
In mice, autoreactive B cells, compared to non-autoreactive 
B cells, appear to be more dependent on BAFF for their 
survival.17,33,47 Evidence presented in the following para-
graphs suggests that an environment rich in BAFF may allow 
survival and expansion of autoreactive B cells, ultimately 
leading to systemic autoimmune disease.
Animal studies
Administration of soluble recombinant BAFF to healthy BALB/c 
mice disrupted the spleen architecture and caused elevation of 
serum Ig concentration (particularly IgM and IgA).31
Transgenic mice overexpressing BAFF produced a 
variety of autoantibodies including rheumatoid factors and 
antibodies against dsDNA and had an expanded population of 
mature B cells. Interestingly, the marginal zone B cell subset 
and plasma cells, but not follicular B cells, were expanded 
in spleens of these transgenic mice. Intense germinal center 
formation was also observed. Peripheral blood B cells from 
???? ??????????????
??????????? ????? ??????????
?????
???????????????????
Figure 1 interaction between BAFF and APRiL and their receptors.
Abbreviations: APRiL, a proliferation-inducing ligand; BAFF, B cell activating factor of the TNF family; BCMA, B-cell maturation antigen; HSPGs, heparin-sulfate proteoglycans; 
TACi, transmembrane activator and calcium modulator and cyclophilin ligand interactor.
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these mice showed an increase in Major Histocompatibility 
Complex class II expression along with high expression of 
a survival (antiapoptotic) factor Bcl-2. Furthermore, these 
mice developed a clinical phenotype closely resembling SLE/
Sjogren’s syndrome with hypergammaglobulinemia, protei-
nuria, and immune-complex-mediated glomerulonephritis. 
Additionally, peripheral blood T cells in these transgenic 
mice displayed an activated effector T-cell phenotype, and 
their number was expanded by at least twofold in the spleen 
and mesenteric lymph nodes.34
Treatment of NZB/NZW-F1 mice with a specific BAFF 
antagonist was able to slow down the disease progression in 
this strain of lupus mice and had a positive effect on overall 
survival.48,49
In NZM model of animal lupus, BAFF-deficient mice 
had a milder phenotype, and BAFF deficiency could pre-
vent acceleration of clinical kidney disease in response to 
treatment with type I IFN.3,50
Treatment of NZBW-F1 mice and NZM 2410 mice with 
either BAFFR-Ig (which only neutralizes BAFF) or TACI-Ig 
(which neutralizes both BAFF and APRIL) showed that 
TACI-Ig was more immunosuppressive, causing a drop in 
serum IgM and IgG levels and Ig-secreting plasma cells in 
the spleen and bone marrow.49 However, both agents had 
a similar effect on clinical disease. When double-deficient 
(BAFF/APRIL) mice were compared to single-deficient 
BAFF mice, a similar effect on renal immunopathology was 
observed, despite pronounced differences in bone marrow 
plasma cells and serum autoantibodies.51 Taken together, 
these results suggest that APRIL may have a minor role in 
lupus pathogenesis.
Concurring with animal studies, treatment of human 
SLE patients (with or without lupus nephritis) with atacicept 
(TACI-Ig) was associated with safety issues related to ~30% 
reduction in serum IgG levels within 4 weeks of treatment. 
So, while atacicept may be an efficient agent for SLE, its 
potential toxicity may outweigh any gains in efficacy.52,53
Interestingly, NZM 2328 mice deficient in BAFF-R still 
develop full blown lupus despite having reduced numbers 
of B cells.54 This suggests that blockade of the BAFF-R 
alone may be therapeutically insufficient to control human 
SLE. At present, there are no clear plans of developing or 
using antibodies against BAFF-R, BCMA, or TACI for the 
treatment of lupus. However, a construct of two BAFF-R 
linked to the Fc domain of human IgG1 has been developed. 
This agent, named briobacept, binds BAFF (human, mouse, 
cynomolgus monkey) but not APRIL, and has been evaluated 
in phase I studies in rheumatoid arthritis (RA), but no plans 
for further development have been made.55
Human SLE
BAFF expression is increased in patients with SLE, and 
a clear correlation between BAFF levels and disease 
activity in SLE has been observed in some studies.19–21 
Biologically active heterotrimers composed of BAFF and 
APRIL are elevated in peripheral blood of SLE patients.56,57 
Interestingly, the membrane form of BAFF is abnormally 
expressed in B cells from patients with active SLE.37 In 
contrast to BAFF, the association between APRIL and SLE 
demonstrated an inverse relationship, suggesting a possible 
protective role for APRIL.58,59 Interestingly, BAFF levels 
are higher in African-American SLE patients as compared 
to European-American SLE patients,60 and a greater degree 
of B cell activation has been observed in African-American 
SLE patients as well.61
Treatment of SLE patients with the anti-BAFF antibody 
belimumab met its primary endpoint in two phase III clinical 
trials in 2011.26,27 Based on these studies, the FDA approved 
belimumab for the treatment of adult patients with SLE. It is 
worth mentioning that patients with active lupus nephritis or 
central nervous system (CNS) disease were excluded from 
these studies. While a study testing the efficacy of belimumab 
in lupus nephritis (BLISS-LN, NCT01639339) is ongoing, no 
similar trial in active CNS disease has been planned.
Interferons and BAFF
Type I and II IFN can regulate BAFF synthesis and thus play 
an important role in lupus pathogenesis. IFN-α can upregulate 
BAFF expression in mouse macrophages, human dendritic 
cells, and monocytes. Evidence of an IFN-signature in human 
SLE is found in about 50% of SLE patients and correlates with 
disease activity.62–66 Administration of type I IFN can lead 
to development of SLE-like syndromes in some patients.67,68 
Therefore, type I IFN is a potential target for treatment of 
SLE, and several neutralizing agents are currently in the pipe-
line, with anifrolumab (anti-type I IFN receptor antibody) 
showing very promising effects in a recent phase II clinical 
trial in SLE.69
IFN-γ could induce a similar upregulation of BAFF in 
various cell types.70,71 For example, BAFF/Blys expression 
on human monocytes, both at the mRNA and protein level, 
was upregulated by IFN-γ up to fourfold.31 Not surprisingly, 
monocytes from SLE patients produced substantially more 
BAFF compared to healthy controls when stimulated with 
the same ligand.72
In SLE patients treated with a neutralizing anti-IFN-α 
antibody, BAFF mRNA expression was downregulated.73 
Moreover, a relatively good correlation existed between 
BAFF and type I IFN levels in patients with SLE.60
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Genetic deletion of the type I IFN receptor (Ifnar I) could 
prevent lupus development in NZB and NZM 2328 mice.74,75 
Vice versa, the administration of type I IFN, or its upregula-
tion, accelerated lupus nephritis, leading to death in several 
strains of lupus-prone mice. However, this was not the case 
with MRL-lpr/lpr mice as Ifnar-deficient MRL mice devel-
oped more severe disease compared to controls.75–78
Therefore, type I IFN and BAFF remain a legible target 
for treatment in SLE.79,80
B cell therapies in SLE
B cells are an important target for treatment of SLE 
patients. At first glimpse, it may look quite illogical why 
very similar treatment approaches aimed at targeting 
B cells result in quite different clinical outcomes in SLE. 
For example, rituximab, a CD20-directed B-cell-depleting 
antibody failed to show efficacy in two recent phase III 
clinical trials in SLE and lupus nephritis (NCT00137969 
and NCT00282347), while belimumab, an anti-BAFF 
agent, became the first FDA approved drug for SLE in 
50 years.26,27,81–83 A potential explanation for this controversy 
comes from the observation that circulating BAFF levels 
actually rise in rituximab-treated patients which may sub-
sequently favor the selection and survival of autoreactive 
B cells and plasmablasts in an environment with very few 
remaining B cells. Furthermore, elevated BAFF levels could 
engage T follicular cells, promoting their interaction with 
autoreactive B cells.84–88
Current portfolio of BAFF 
(and APRIL) inhibitors
The portfolio of BAFF inhibitors includes belimumab (anti-
BAFF antibody), blisibimod (anti-BAFF peptibody), tabal-
umab (anti-BAFF antibody), briobacept (BAFF receptor, 
inhibits only BAFF), atacicept (TACI receptor, inhibits 
both BAFF and APRIL), and anti-BAFF-R. In contrast, 
GSK2857916, an antibody drug conjugate, antagonizes only 
the BCMA receptor and is currently undergoing phase I study 
in multiple myeloma (NCT02064387) with no immediate 
plans for clinical studies in SLE.
Briobacept, consisting of an extracellular domain of 
BAFF-R fused to human IgG-Fc, has been evaluated in 
a phase I study in patients with RA. A report in the form 
of an abstract has been published in 2008, but since then 
further advancement to phase II or III clinical studies has 
been abandoned.55
Another BAFF-neutralizing agent, tabalumab, achieved 
its primary endpoint in a recent phase III study ILLUMI-
NATE-2 (NCT01205438).89 However, important secondary 
endpoints such as time to severe flare, corticosteroid-sparing 
effect, and fatigue were not met. Therefore, the drug devel-
oper, Eli Lilly Co in 2014 decided to stop further clinical 
development of tabalumab in SLE.
Another interesting agent in development is atacicept, 
which neutralizes both BAFF and APRIL. While atacicept 
may still offer hopes for SLE, higher risk of serious infec-
tions and unsafe drop in serum IgG were observed in recent 
phase II/III trials.52,90
Several recent review articles have summarized clinical 
trials with the above agents, and thus will not be further 
discussed in this review.91–94
Development of A-623/AMG623/
blisibimod as a novel high potency 
and selective BAFF-neutralizing 
agent
Dr Hsu et al95 at Amgen’s Department of Inflammation were 
looking for a new BAFF-neutralizing agent that would bind 
and neutralize both membrane-bound and soluble BAFF 
with high affinity. Their goal was to screen a 12-mer con-
strained phage library over Fc-BAFF protein immobilized 
on protein-A-coated magnetic beads. The next step involved 
fusing BAFF-binding peptides in tandem copies in-frame 
to the N-terminal part of the human IgG1-Fc region. The 
resulting construct (named peptibody) was then expressed 
in Escherichia coli. Purified peptibodies have a unique tet-
ravalent structure, but since they are produced in E. coli, they 
lack the posttranslational glycosylation. A concern remains 
that BAFF-binding peptides in blisibimod may potentially 
become immunogenic in humans, causing the induction 
of neutralizing antibodies that will subsequently diminish 
blisibimod’s potency for BAFF.
In vitro B cell proliferation and 
affinity studies with A-623/AMG623/
blisibimod
These novel peptibodies were first studied in an anti-IgM 
plus BAFF-mediated B cell proliferation assay. AMG623 
showed high affinity for BAFF and inhibited BAFF (and 
anti-IgM)-mediated B cell proliferation at low nanomolar 
range (IC-50 at 6 ng/mL).
AMG623 was also tested for its ability to inhibit binding 
of human BAFF, murine BAFF, or murine APRIL to Biacore 
chips containing immobilized soluble receptors. AMG623 
blocked binding equally well of both human and murine 
BAFF to BAFF-R, TACI, and BCMA, but had no effect on 
APRIL binding to its receptors TACI and BCMA.95
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Animal models
Contrasting with belimumab, which lacks cross reactivity 
with murine BAFF,96,97 AMG623 could block murine BAFF 
activity in vitro. It was subsequently studied in healthy ani-
mals and in animal models of SLE and RA. Studies in healthy 
BALB/c mice showed the ability of AMG623 to reduce the 
number of B cells in peripheral blood and in spleens. Further 
animal testing showed the ability of AMG623, when injected 
intraperitoneally for 5 months, to delay the onset of protei-
nuria and prolong survival in lupus-prone NZB/NZW-F1 
mice. However, this beneficial effect in lupus-prone mice 
was short-lived and disappeared 3 months after the last injec-
tion, suggesting that the defect in immune tolerance leading 
to disease induction in this model of lupus was not restored 
and that continuous BAFF inhibition is required.
Similar to animal models of lupus, AMG623 was 
also effective in collagen-induced arthritis, a mouse 
model of RA.95
Clinical trials with blisibimod
early-phase trials
Stohl et al98 conducted early-phase clinical trials with blisi-
bimod in SLE to characterize safety and tolerability. Adult 
patients with mild stable or inactive SLE (mean SLEDAI ~3) 
on standard treatment (including prednisone #10 mg daily) 
were enrolled in two early-phase trials with blisibimod. The 
primary endpoints of both trials were safety and tolerability; 
additional secondary endpoints were pharmacokinetic and 
pharmacodynamic parameters, and exploratory endpoints 
such as changes in peripheral B cell counts and expression 
of B cell surface markers.
In the phase Ia ascending single-dose study 
(NCT02443506), patients were sequentially enrolled into 
one of seven dose cohorts and randomized 3:1 to single dose 
of blisibimod, administered either subcutaneous (SC) or 
intravenous (IV), or placebo. A total of 56 participants were 
randomized, and 54 received the assigned treatment. Partici-
pants were followed up to 42 days postdose, and participants 
in the highest dose cohort (6.0 mg/kg IV) completed a 4-week 
extension after end-of-study visit. Comparable proportion of 
participants in the blisibimod (70%) and control (79%) arms 
experienced $1 adverse effect (AE). A total of two serious 
AEs (SAE) were reported, with one each in the blisibimod 
and control arms, related to the study drug.
In the phase Ib ascending multidose study (NCT02411136), 
patients were sequentially enrolled into one of four dose 
cohorts and randomized 4:1 to receive 4 weekly doses of 
blisibimod (SC or IV) or placebo. A total of 64 participants 
were randomized, while 63 received the assigned treatment; 
4 participants (2 in each group) withdrew due to an AE. 
Similar proportion of participants in each group reported $1 
AE (96% blisibimod vs 92% placebo); nine SAEs were 
reported in eight participants (5 in blisibimod, 3 in placebo). 
In the blisibimod arm, SAEs were lupus flare (polyarthritis), 
depression, chest pain with fever, and syncope; one 
participant experienced QTc prolongation possibly related 
to the study drug.
The overall results of these two early-phase clinical 
trials confirmed that blisibimod had favorable safety and 
tolerability compared with placebo, providing support for 
further study in phase II trials. However, a large proportion 
of participants tested positive for neutralizing antibodies, 
which could be of some concern. Additional exploratory 
analyses demonstrated blisibimod’s effect on decreasing 
peripheral B cell counts and changing B cell populations, 
with relative decrease in naïve B cells and increase in 
memory B cell compartments via BAFF-mediated differ-
ential B cell effects.
PeARL-SC (NCT01162681)
After promising phase I studies, PEARL-SC,99 a random-
ized, double-blind, placebo-controlled, phase II study was 
conducted to assess efficacy and safety of SC blisibimod in 
patients with active SLE (baseline SELENA-SLEDAI $6). 
The primary outcome was the proportion of responders in the 
blisibimod pooled group compared with the placebo pooled 
group meeting the composite endpoint SLE responder index 
(SRI-5) at 24 weeks. This multicenter international study 
enrolled 547 participants, randomized in parallel to receive 
blisibimod SC (either 100 mg once weekly, 200 mg once 
weekly, or 200 mg every 4 weeks) or placebo. The major 
exclusions were SLE patients with severe lupus nephritis, 
CNS lupus, and vasculitis.
Patient baseline characteristics were similar between 
groups, except for immunosuppressive use, which was higher 
in the placebo group (52.3%) compared with the control 
group (38.2%). In both groups, participants were predomi-
nantly female (94%), Hispanic (71%), and with active SLE 
(mean SELENA-SLEDAI ~10) with $3 organ domains 
involved (61%–65%). The most common SLE disease 
manifestations were mucocutaneous (91%), immunological 
(77%), and musculoskeletal (75%); renal manifestations were 
observed in 14%. Treatment with corticosteroids (~90%) and 
antimalarials (~70%) was common in both groups.
The primary efficacy endpoint for the study, the pro-
portion of SRI-5 responders for blisibimod compared with 
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placebo pooled groups, was not met. The proportion of 
SRI-5 responders in the highest blisibimod group (200 mg 
once weekly) was greater than pooled and regimen-matched 
placebo groups; however, this was not statistically significant. 
Similar trends were observed for modified SRI responses with 
blisibimod, ie, SRI-7 and SRI-8, compared with regimen-
matched placebo. Additional subgroup analyses revealed 
favorable treatment response with blisibimod compared with 
placebo for severe SLE, defined as high baseline disease 
activity (SELENA-SLEDAI $10) and on corticosteroids. 
A higher difference in the responder rates (∆SRI) between 
blisibimod and placebo was observed with increasing SRI 
responses, ie, from SRI-5 to SRI-8.
Compared to placebo, trends favoring blisibimod were 
seen for cumulative probability of severe flare and time to 
first severe flare, especially for the highest dose (200 mg once 
weekly). Among participants on prednisone .7.5 mg/d at 
baseline, more participants on the highest dose blisibimod 
(200 mg once weekly) were able to taper prednisone 
dose #7.5 mg/d compared with placebo (11.9% vs 9.5%). 
Subgroup analysis in participants with baseline proteinuria 
(urine protein to creatinine ratio of 1–6 g/g) achieved a greater 
mean reduction with blisibimod. Similar trends were seen for 
disease activity markers of SLE, with significant reduction 
of B cells and ds-DNA and increase in C3 and C4.
Further, Petri et al100 reported on the effects of blisibimod 
on patient-reported fatigue and disease activity in PEARL-SC. 
Improvements in fatigue measured by the FACIT-Fatigue 
score were seen in both groups, but were more profound with 
higher dose blisibimod (100 mg and 200 mg once weekly), 
exceeding the minimal clinically important difference in 
SLE (P,0.05). SRI-5 responders had significantly higher 
mean changes in fatigue compared with nonresponders. 
Improvements in fatigue, however, correlated poorly with 
disease activity. In terms of safety, a comparable propor-
tion of participants in the blisibimod and placebo groups 
reported any AE (82.5% vs 85%), while fewer blisibimod-
treated participants reported SAEs (11.1% vs 15.8%); 
overall, no differences were observed for severe infections, 
death, or malignancy. The presence of antidrug antibodies 
was not reported, given the high rates of assay positivity in 
blisibimod-naïve patients, which according to the authors 
needs further refinement. Thus, the possibility of immu-
nogenicity to blisibimod with repeated exposure remains a 
concern for sustained clinical efficacy.
Despite not meeting its primary outcome, the PEARL-SC 
study redemonstrated safety and tolerability of blisibimod, 
and provided a hint of efficacy (especially for the highest 
blisibimod dose of 200 mg once weekly) in SLE patients 
with severe disease meeting a higher responder threshold 
(SRI-8). This subpopulation of SLE would benefit from 
further targeted study in phase III trials. On completion of 
PEARL-SC, 382 participants were enrolled in the open-label 
blisibimod extension study, PEARL-OLE, with prelimi-
nary reports demonstrating favorable long-term safety of 
blisibimod.101,102
Early-phase clinical trials of blisibimod in SLE are 
summarized in Table 1.
Table 1 early-phase clinical trials with blisibimod in SLe
Clinical trial Phase Status SLE population Exclusion Primary outcome/results Reference
PeARL-SC
NCT01162681
ii Completed
4-2012
Age $18 years
SeLeNA-SLeDAi $6
On stable GC dose
+ANA and/or +ds-DNA
Active CNS
Active LN
vasculitis
Proportion of patients 
achieving SRi-5 at 24 weeks
Furie et al99
PeARL-OLe
NCT01305746
ii Completed
10-2013
Same as PeARL-SC Same as PeARL-SC Long-term safety Furie et al101
NCT02443506 ia Completed
6-2007
Age 18–65 years
“Mild” SLea
Stable or inactive SLe
On Pred #10 mg/d
+ANA
Active CNS
Active LN
vasculitis
Safety and tolerability Stohl et al98
NCT02411136 ib Completed
10-2007
Age 18–65 years
“Mild” SLea
Stable or inactive SLe
On Pred #10 mg/d
+ANA
Active CNS
Active LN
vasculitis
Safety and tolerability Stohl et al98
Note: aAssessed by investigator (no objective measure reported).
Abbreviations: SLE, systemic lupus erythematosus; OLE, open label extension; SELENA-SLEDAI, SLE disease activity index with SELENA modification; SRI, SLE responder 
index; GC, glucocorticoid; ANA, antinuclear antibody; ds-DNA, double stranded DNA; +, positive; CNS, central nervous system; LN, lupus nephritis.
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Late-phase trials
CHABLiS-SC1 (NCT01395745)
CHABLIS-SC1,102 a phase III randomized, double-blind, 
placebo-controlled trial, builds on prior successful early 
phase trials with blisibimod in SLE with the aim of target-
ing the responder populations identified in the PEARL-SC 
trial.102 This study enrolled 442 participants with active 
SLE (SELENA-SLEDAI $10) on systemic corticosteroids, 
randomized to blisibimod (200 mg SC once weekly) or 
placebo in addition to standard of care treatment. The primary 
endpoint was defined as SRI-6 at 52 weeks; additional sec-
ondary endpoints included time to first severe SLE flare, 
change in the number of tender and swollen joints, change 
in mucocutaneous disease activity, proportion of participants 
achieving prednisone #7.5 mg/d, and effect on biomarkers 
and safety. Due to the difficulty in evaluating new drug effect 
on background lupus treatment and high responder rates in 
placebo groups, this trial employed a strict requirement for 
early tapering of systemic corticosteroids after week 8 with 
the goal of achieving prednisone #7.5 mg/d.102 The study 
was completed in September 2016; however, no study results 
have been reported yet.
CHABLiS 7.5 (NCT02514967)
CHABLIS 7.5 is a phase III randomized, double-blind, 
placebo-controlled trial to evaluate the efficacy and safety 
of blisibimod in SLE participants with or without lupus 
nephritis. The study aims to enroll 350 patients with active 
SLE defined as SELENA-SLEDAI $10 despite systemic 
corticosteroids, who are positive for ds-DNA and have low 
complements. Participants will be randomized to blisibimod 
(200 mg SC once weekly) or placebo. The primary outcome 
is SRI-6 at 52 weeks, while secondary outcomes will be 
similar to those measured in CHABLIS-SC1. This trial is 
actively enrolling participants since June 2016 with the goal 
of completion in December 2018.
Late-phase clinical trials of blisibimod are summarized 
in Table 2.
Conclusion
The identification of BAFF’s key role as a B cell survival, 
activation, and differentiation cytokine involved in SLE 
pathogenesis has led to the development of novel anti-BAFF 
agents with promising clinical results in SLE. The novel 
biologic agent blisibimod is building on the success of 
belimumab by targeting both soluble and membrane-bound 
BAFF. Early-phase clinical trials of blisibimod have proven 
its safety and tolerability and have provided a hint of effi-
cacy, specifically in a subpopulation of SLE patients with 
higher disease activity. Blisibimod’s immunogenicity, which 
leads to the emergence of neutralizing antibodies reported in 
clinical trials, likely driven by its phage manufacturing pro-
cess, remains a clinical concern. Despite this clinical hurdle, 
anti-BAFF therapy remains a promising new therapeutic 
option for the management of patients with SLE, and the 
results of late phase clinical trials are eagerly awaited.
This review has focused on the state of the art knowledge 
about the new anti-BAFF agent, named blisibimod, and its 
potential advantage over other BAFF-neutralizing agents 
for the treatment of lupus. However, numerous other 
pharmaceuticals, including small-molecular signaling 
pathway inhibitors (eg, Bruton tyrosine kinase inhibitors or 
Table 2 Late-phase clinical trials with blisibimod in SLe
Clinical trial Phase Status SLE population Exclusion criteria Primary outcome/results Reference
CHABLiS-SC1
NCT01395745
iii Completed
9-2016
Age $18 years
SeLeNA-SLeDAi $10
On stable GC dose
+ANA and/or +ds-DNA
Active CNS
Active LN
vasculitis
Cytopenia
Proportion of patients 
achieving SRi at 52 weeks 
Scheinberg 
et al102
CHABLiS-SC2
NCT02074020
iii withdrawn prior 
to enrollment
Age $18 years
SeLeNA-SLeDAi $10
±Stable LN
On stable GC dose
+ANA and/or +ds-DNA
Active CNS
vasculitis
Cytopenia
Proportion of patients 
achieving SRi-8 at 52 weeks
NA
CHABLiS 7.5
NCT02514967
iii Recruiting
6-2016
Age $18 years
SeLeNA-SLeDAi $10
±Stable LN
On stable GC dose
+ds-DNA and low C3 or C4
Active CNS Proportion of patients 
achieving SRi-6 at 52 weeks
NA
Abbreviations: SLE, systemic lupus erythematosus; SELENA-SLEDAI, SLE disease activity index with SELENA modification; SRI, SLE responder index; GC, glucocorticoid; 
ANA, antinuclear antibody; ds-DNA, double stranded DNA; +, positive; CNS, central nervous system; LN, lupus nephritis; SRi, SLe responder index; NA, not available; 
C3, complement component 3; C4, complement component 4.
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proteasome inhibitors) are in various stages of preclinical and 
clinical development. It remains to be determined whether 
antibody-based neutralization of B cells may have any poten-
tial clinical advantages over these small-molecular inhibitors. 
Hopefully, we will not need to wait another 50 years for the 
next drug to be approved for the treatment of lupus.
Disclosure
The authors report no conflicts of interest in this work.
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